12th Annual Scientific Meeting
16 – 18 February, 2016 // The Fairmont, Washington DC, USA
Distinguished Poster Award Recipients:
|
||
|
All Poster PDFs and Abstracts are available at the end of the second day. |
||
Day 1 (16 February 2016) |
||
| Presidential Welcome | S Romano slides video |
|
| Improving Transparency of Clinical Trial Data | Chairs: M Weiser A Kalali |
|
| Session Overview | ||
| A Holistic Approach to Data Transparency: Raising the Standard for All Stakeholders | A Kalali* |
|
| Rates of Non-Publication of Trials Funded by the Stanley Medical Research Institute | M Weiser slides video |
|
| Data Transparency Changes in NIMH Clinical Trials | N Gogtay slides video |
|
| Data Transparency: A View from Industry | R Lasser slides video |
|
| Regulatory Perspective on Complete Data for Registration Trials: Transparency, Access and Interpretation | T Laughren slides video |
|
| Practical Issues for Patients, Family and the Public | D Fuller slides video |
|
| Panel Discussion | Speakers |
|
| Concluding Comments | M Weiser video (includes panel) |
|
Working Group Dinners |
||
| Adaptive Design | Chairs: J Kando R Marcus Working Group Slides: slides |
|
| Addressing Methodological Challenges in International CNS Clinical Trials | Chairs: R Keefe A Kalali Working Group Summary: slides |
|
| Algorithms/Flags to Identify Clinical Inconsistency in the Use of Rating Scales in CNS RCTs | Chairs: J Rabinowitz N Schooler Working Group Slides: slides |
|
| Biomarkers in Schizophrenia | Chairs: S Potkin D Goff Working Group Slides: slides |
|
| Behavioral and Psychiatric Symptoms and Dementia | Chairs: L Ereshefsky D Miller Working Group Slides: slides |
|
| Cognitive Assessment in CTs of AD and its Precursors | Chairs: H Posner P Harvey Working Group Slides: Ryan Hendrix Walton Lasser |
|
| Identifying and Analyzing Adverse Events Related to Abuse and Dependence Potential in CTs | Chairs: B Setnick M Sokolowska M Klein Working Group Slides: slides |
|
Day 2 (17 February 2016) |
||
| Drug Repositioning in CNS: Can We Give a Hand to Serendipity and Promiscuity? | Chairs: M Davidson C Canuso |
|
| Introduction | M Davidson slides video |
|
| Accessing Compounds: Partnering with Industry | C Canuso slides video |
|
| NIH Drug Repositioning Mechanisms: Examples that Support CNS Indications from NCATS and NIMH | W Potter slides video |
|
| What to Try When you Are Out of Ideas: Repositioning—The Stanley Experience | M Weiser slides video |
|
| What Can Be Learned from Observational Patient-Level Databases? | P Stang slides video |
|
| Drug Repositioning Platforms to Predict Drug-Disease Signatures | S Dakshanamurthy slides video |
|
| Panel | M Davidson Speakers video |
|
Parallel Sessions |
||
| Session A: Novel Developments to Address Methodological Issues in Autism Spectrum Disorders | Chairs: L Alphs L Gault G Pandina |
|
| Introduction | L Alphs slides video |
|
| Challenges to Patient Identification in Clinical Trials for the Treatment of Autism Spectrum Disorder | L Gault slides video |
|
| Lessons Learned: Development of a GABA-B Receptor Agonist for ASD and Fragile X | P Wang slides video |
|
| Autism Spectrum Disorder (ASD): Outcome Measures and Potential Biomarkers | G Pandina slides video |
|
| The Translational Neurobiology of Autism | D Murphy slides video |
|
| Regulatory considerations when conducting clinical trials for the treatment of Autism Spectrum Disorder | T Farchione slides video |
|
| Panel Discussion: How Do We Partner with Stakeholders to Move Autism Research Forward, and Facilitate Biomarker Validation and Endpoint Development? | Speakers S Zukin slidesL Brady slides video (includes panel) |
|
| Session B: Mitigating the Effects of Nonadherence in Clinical Trials | Chairs: T Shiovitz E Bain |
|
| Introduction | T Shiovitz | |
| Artifactual Nonadherence: Inappropriate Behavior Specific to the Clinical Trial Setting | T Shiovitz slides video (includes intro) |
|
| The Impact of Noninformative Data on Clinical Trials | E Bain slides video |
|
| Adherence Biomarkers, Technologies and Subject Registries | P Skolnick slides video |
|
| Where and How to Act to Identify and Mitigate the Effects of Nonadherence | D McCann slides video |
|
| Regulatory Considerations in Addressing Nonadherence in Clinical Trials | T Laughren slides video |
|
| Summary of Working Group Recommendations | E Bain slides video |
|
| Panel Discussion | A Hanina Speakers slides video |
|
| Poster Session/Reception | Poster PDFs (linked to abstract titles) |
|
Day 3 (18 February 2016) |
||
| Presentation of the Andrew C. Leon Distinguished Career Award | ||
| Network Meta-Analysis: Integrating Results of Direct and Indirect Treatment Comparisons | Chairs: N Schooler M Stewart G Haynes |
|
| Introduction | N Schooler video |
|
| Network Meta-Analysis: A Brief Tutorial | J Cappelleri slides video |
|
| Critical Issues Raised by Network Meta-Analysis: Examples from Anti-Depressants and Anti-Manic Drug Analyses | A Cipriani slides video |
|
| Network Meta-Analysis of Anti-Psychotics for Schizophrenia: Clinical Implications | J Davis slides video |
|
| Panel Presentations | A Nierenberg slides video J Kane videoL Alphs slides videoR Goldman slides videoG Haynes slides videoPanel Discussion video |
|
| Meeting Adjourned |
||
| *Presentation not released | ||